AstraZeneca (AZN) said Wednesday that an interim analysis of the phase 3 trial of its experimental therapy, camizestrant, combined with a cyclin-dependent kinase inhibitor showed statistically significant and clinically meaningful improvement in progression-free survival in certain breast cancer patients compared to standard of care.
Although key secondary endpoints such as time-to-second disease progression and overall survival were not fully mature, the combination therapy showed a trend toward improvement, the company said.
The drugmaker said the trial will continue to assess secondary endpoints as planned.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.